Table 1 Characteristics of all vaccinated patients
Pt | Gender | Age (y) | Country | Disease | Disease activity | Biological | Other DMARDs | Vaccination | Adverse events | Flare |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Female | 7 | USA | sJIA | Inactive | Anakinra 4 mg/kg/day | Prednisone (0.12 mg/kg/day) Methotrexate Leflunomide Thalidomide | Varicella zoster (booster) | Varicella zoster infection | – |
2 | Female | 1 | Turkey | sJIA | Inactive | Canakinumab 4 mg/kg/2 months | Prednisone (5 mg/day) Methotrexate | MMR booster | Pneumonia | Yes |
3 | Male | 2 | Turkey | sJIA | Inactive | Tocilizumab 12 mg/kg/monthly | Prednisone (2.5 mg/day) | Oral polio vaccine | Diarrhea | – |
4 | Male | 12 | USA | MKD | Inactive | Anakinraa 100 mg/day (STOP 3-4D-1D) | – | Varicella zoster (booster) | – | Yes |
5 | Male | 9 | USA | MKD | Inactive | Anakinraa 150 mg during flare (STOP 2D-1D) | – | Varicella zoster (booster) | – | Yes |
6 | Female | 4 | USA | MKD | Partially active | Canakinumaba 4 mg/kg/6 weeks (STOP 3 M–3 M) | Varicella zoster (first vaccine) and MMR first vaccine | – | Yes | |
7 | Female | 2 | Turkey | FMF | Inactive | Canakinumab 4 mg/kg/monthly | Prednisone (2.5 mg/day) Colchicine | MMR booster | – | Yes |
8 | Female | 9 | Netherlands | sJIA | Inactive | Anakinraa 1.7 mg/kg/2 days (STOP 2D-3D) | Methotrexate | MMR booster | – | Yes |
9 | Male | 3 | Netherlands | sJIA | Inactive | Tocilizumab 132 mg/14 days) | Prednisone (2.5 mg/day) | Varicella zoster (first vaccine) | – | Yes |
10 | Male | 12 | Italy | CAPS | Inactive | Anakinraa 1.5 mg/kg/day (STOP 3D-14D) | Methylprednisolone (0.06 mg/kg/day) | MMR booster | – | – |
11 | Female | 12 | Italy | MKD | Partially active | Anakinraa 1.4 mg/kg/day (STOP 3D-28D) | – | MMR booster | – | – |
12 | Female | 9 | Netherlands | sJIA | Inactive | Anakinra 40 mg/3 days | – | MMR booster | – | – |
13 | Male | 9 | Netherlands | sJIA | Inactive | Tocilizumab 8 mg/kg/2 weeks | Methotrexate | MMR booster | – | – |
14 | Female | 58 | United Kingdom | CAPS | Inactive | Anakinraa 100 mg/day (STOP 3D-3D) | – | Yellow fever (first vaccine) | – | – |
15 | Female | 28 | United Kingdom | CAPS | Inactive | Anakinraa 100 mg/day (STOP 3D-3D) | – | Yellow fever (first vaccine) | – | – |
16 | Female | 26 | United Kingdom | CAPS | Inactive | Anakinraa 100 mg/day (STOP 3D-3D) | – | Yellow fever (first vaccine) | – | – |
17 | Female | 44 | United Kingdom | CAPS | Inactive | Canakinumab (150 mg/2 months) | – | Yellow fever (first vaccine) | – | – |